Skip to main content

Market Overview

Immunoprecise Stock Soars As COVID-19 Antibody Cocktail Shows Neutralizing Activity Against Delta Variant In Animal Study

Share:
Immunoprecise Stock Soars As COVID-19 Antibody Cocktail Shows Neutralizing Activity Against Delta Variant In Animal Study
  • Immunoprecise Antibodies Ltd (NASDAQ: IPAhas announced new results from its TATX-03 PolyTope Therapy, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta (B.1.617.2) variant.
  • The therapy is a four monoclonal antibody cocktail developed for the potential prevention and treatment of COVID-19.
  • IPA previously announced that TATX-03 demonstrated strong efficacy in reducing viral load in vivo using a hamster challenge model and potently neutralized pseudovirus of Alpha (B.1.1.7) and Beta (B.1.351) variants in vitro.
  • Additional evaluation of virus neutralization potency in an in vitro pseudovirus-based assay revealed that IPA's TATX-03 anti-SARS-CoV-2 antibody cocktail is also not affected by the rapidly spreading Delta variant (B.1.617.2). 
  • Parallel reactivity screening of the individual antibodies of TATX-03 revealed differential susceptibility of the lead components towards the Delta (B.1.617.1) variant, with the majority showing maintained binding.
  • Price Action: IPA shares are up 23.3% at $6.89 during the premarket session on the last check Thursday.
 

Related Articles (IPA)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech Long Ideas News Health Care Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com